LONDON (Thomson Financial) - Oxford Biomedica Plc's cancer vaccination
TroVax will not meet its defined goals in a late stage study for renal cancer,
according to a key review board.
While the trial will continue, the Drug Safety Monitoring Board has ruled
that there should be no more vaccinations administered.
Chief executive Mike McDonald said: "This news is clearly disappointing.
However, there is good reason to continue the study and potentially a late
survival benefit for TroVax may still be demonstrated."
The drug is being developed in partnership with Sanofi-Aventis SA.
ben.deighton@thomsonreuters.com
bsd
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|